Compare WTTR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | SNDX |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2017 | 2014 |
| Metric | WTTR | SNDX |
|---|---|---|
| Price | $16.63 | $21.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $16.67 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,528,930,000.00 | $172,352,000.00 |
| Revenue This Year | $2.11 | $107.19 |
| Revenue Next Year | $4.94 | $41.88 |
| P/E Ratio | $69.16 | ★ N/A |
| Revenue Growth | 120.79 | ★ 627.84 |
| 52 Week Low | $7.20 | $8.59 |
| 52 Week High | $17.04 | $25.59 |
| Indicator | WTTR | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 34.89 |
| Support Level | $9.72 | $19.46 |
| Resistance Level | N/A | $22.33 |
| Average True Range (ATR) | 0.55 | 0.96 |
| MACD | 0.12 | -0.45 |
| Stochastic Oscillator | 86.35 | 9.96 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.